Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma

Wargotz, Eric S.; Norris, Henry J.

doi:10.1016/0046-8177(89)90149-4

Cited by 303 publications

(268 citation statements)

References 14 publications

Supporting

Mentioning

250

Contrasting

Unclassified

Order By: Relevance

“…Previously, ultrastructural and immunohistochemical studies indicated that matrix-producing carcinoma had an epithelial nature: the presence of intercellular junctions such as desmosomes, tonofilaments in the cytoplasm of cancer cells, and positivity for CKs and EMA. 2,13,14 Ultrastructural findings of metaplastic cells within the matrix revealed dilated segments of rough endoplasmic reticulum containing finely granular, homogeneous, pale-staining matrix materials identical to those seen in intercellular spaces. 2 As immunohistochemical examination of the current cases also showed diffuse and/or focal positivity for CKs and EMA in overtly carcinomatous cells and metaplastic cells, matrix-producing carcinoma was presumed to be derived from mammary epithelial cells.…”

Section: Discussionmentioning

confidence: 98%

“…2,13,14 Ultrastructural findings of metaplastic cells within the matrix revealed dilated segments of rough endoplasmic reticulum containing finely granular, homogeneous, pale-staining matrix materials identical to those seen in intercellular spaces. 2 As immunohistochemical examination of the current cases also showed diffuse and/or focal positivity for CKs and EMA in overtly carcinomatous cells and metaplastic cells, matrix-producing carcinoma was presumed to be derived from mammary epithelial cells. In the current cases, the desmosome-like intercellular junction structures and tonofilaments in carcinomatous cells strongly support that matrixproducing carcinoma was of epithelial origin.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Cartilaginous features in matrix-producing carcinoma of the breast: four cases report with histochemical and immunohistochemical analysis of matrix molecules

et al. 2008

View full text Add to dashboard Cite

Matrix-producing carcinoma of the breast is a well-established entity in the group of metaplastic carcinoma, which is histologically characterized by myxochondroid matrix formation and is extremely rare. We describe here four additional cases of matrix-producing carcinoma of the breast. All cases of matrix-producing carcinoma show nest-like, sheet-like, and cord-like growth of tumor cells with cellular atypia, in addition to scattered cancer cells within myxoid or myxohyalinous stroma. Three of four cases showed an acellular or oligocellular matrix-rich zone in the center of the tumor. Immunohistochemically, cancer cells of all cases were positive for cytokeratins and epithelial membrane antigens and partially positive for sox9 and p63. Aggrecan and type II collagen, which are cartilage-specific matrix molecules, were deposited in the stroma of all cases. Type I and type IV collagens were also deposited on the stroma of all cases. These findings suggest that, although cancer cells of matrix-producing carcinoma of the breast are epithelial, they transdifferentiate to chondrocyte-like cells and produce cartilage-specific matrix molecules, which are useful markers for diagnosing matrix-producing carcinoma. Modern Pathology (2008Pathology ( ) 21, 1282Pathology ( -1292 doi:10.1038/modpathol.2008 published online 11 July 2008 Keywords: aggrecan; collagens; matrix-producing carcinoma; breast; immunohistochemistry; electron-microscopy Matrix-producing carcinoma of the breast is an extremely rare and specialized variant of metaplastic carcinoma of the breast, which is a well-established entity; 1,2 because of its rarity, the features of its stroma have remained unclear.Aggrecan is a cartilage-specific major proteoglycan. 3 This macromolecule deposits in the hypertrophic zones of growth plate cartilage, 4 although it was reported to deposit in the salivary pleomorphic adenoma, which frequently showed mesenchyme-like elements, including myxoid and chondroid tissues. 5,6 Type II collagen, which is a cartilage-specific major collagen, and chondromodulin-I (ChM-I), which is cartilage-specific noncollagenous matrix protein, 4,7,8 are deposited in the normal cartilaginous matrix. These molecules can be useful markers of cartilaginous differentiation. As sox9 is a transcription factor, the expression of which induces cartilaginous differentiation, 9-11 this molecule is also a useful marker of chondroid differentiation in normal and neoplastic tissues. [9][10][11][12] We investigated the deposition of matrix molecules in matrix-producing carcinoma of the breast, histochemically and immunohistochemically.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 98%

Cartilaginous features in matrix-producing carcinoma of the breast: four cases report with histochemical and immunohistochemical analysis of matrix molecules

et al. 2008

View full text Add to dashboard Cite

show abstract

“…33,36,37,[40][41][42][43][44] NGFR positivity was significantly higher in metaplastic breast carcinomas when compared to that of a population-based cohort of breast cancers.…”

Section: Discussionmentioning

confidence: 99%

“…Representative sections of two adenomyoepitheliomas and 20 metaplastic breast carcinomas (reviewed by JSRF, FM and FCS and reclassified as seven spindle cell carcinomas, 33 two carcinomas with heterologous elements, 34 six carcinomas with squamous metaplasia 35 and five matrix-producing breast carcinomas 36 ) were analysed.…”

Section: Tumours With Myoepithelial Differentiationmentioning

confidence: 99%

Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue

et al. 2006

View full text Add to dashboard Cite

Nerve growth factor receptor (NGFR) is a transmembrane glycoprotein without intrinsic tyrosine kinase activity, whose expression is not restricted to neural cells. NGFR is reported to act as a tumour suppressor, negatively regulating cell growth and proliferation. NGFR expression was immunohistochemically analysed in normal breast tissue and in 140 benign, biphasic and preinvasive breast lesions, in 22 tumours with myoepithelial differentiation and in two cohorts of breast cancer patients: a series of 245 invasive breast carcinomas studied with tissue microarrays and 37 high-grade invasive ductal carcinomas with basal-like immunophenotype. NGFR consistently displayed membrane reactivity in myoepithelial cells arranged as a continuous layer around normal ducts and lobular units, intralobular fibroblasts, vascular adventitia and nerve bundles. Myoepithelial cells of benign proliferations and pre-invasive lesions were consistently positive for NGFR. Scattered NGFRpositive cells were observed in solid areas of six out of nine cases of hyperplasia of usual type, whereas in flat atypia, lobular carcinoma in situ and virtually all cases of ductal carcinoma in situ (97.5%), NGFR was restricted to the myoepithelial layer. Positivity for NGFR was observed in 11 out of 245 (4.5%) breast carcinomas, nine out of 20 (45%) metaplastic breast carcinomas and 14 out of 37 (38%) basal-like breast carcinomas. NGFR expression in invasive tumours significantly correlated with that of cytokeratins 5/6 (Po0.05), 14 (Po0.0001) and 17 (Po0.0005) and EGFR (Po0.0001) and displayed an inverse correlation with oestrogen and progesterone receptors (both, Po0.0001). NGFR showed a statistically significant association with longer disease-free (Po0.05) and overall survival (Po0.01) in the cohort of patients with basal-like carcinomas. This study demonstrates the usefulness of NGFR as a new adjunct marker to identify myoepithelial cells in preinvasive lesions and myoepithelial differentiation in breast carcinomas. Furthermore, provisional data in a small number of basal-like breast carcinomas suggest that NGFR may identify a subgroup of basal-like breast carcinomas with good prognosis.

show abstract

“…Microscopically, metaplastic carcinomas are highly distinctive but vary in the types, extent. Most reports divide metaplastic carcinomas into two broad categories: those that show squamous differentiation 4 and those that feature heterologous elements, such as, cartilage, bone, muscle, adipose tissue, vascular elements, and even melanocytes, among others 3,8 . Investigators at the Armed Forces Institute of Pathology categorize metaplastic carcinoma into five categories: squamous cell carcinomas 5 , spindle cell carcinomas 9 , carcinosarcoma 10 , matrix-producing carcinomas 4 , and carcinomas with osteoclastlike giant cells 11 .…”

Section: Discussionmentioning

confidence: 99%

A Rare Case on Metaplastic Squamous Cell Carcinoma of Breast

Jasani¹

2012

Int J of Biomed & Adv Res

View full text Add to dashboard Cite

Metaplastic breast carcinomas represent a morphologically heterogeneous group of invasive breast cancers in which a variable portion of the glandular epithelial cells comprising the tumor have undergone transformation in an alternate cell type -either a nonglandular epithelial cell type or a mesenchymal cell type. Metaplastic carcinomas are uncommon lesions, representing less than < 5% of all invasive breast cancer. This is a case of 51 year old female with left breast swelling since 3 months. She underwent Modified Radical Mastectomy. The histopathological findings were in favour of diagnosis invasive metaplastic carcinoma of breast -squamous cell variant -well differentiated.

show abstract

Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma

Cited by 303 publications

References 14 publications

Cartilaginous features in matrix-producing carcinoma of the breast: four cases report with histochemical and immunohistochemical analysis of matrix molecules

Cartilaginous features in matrix-producing carcinoma of the breast: four cases report with histochemical and immunohistochemical analysis of matrix molecules

Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue

A Rare Case on Metaplastic Squamous Cell Carcinoma of Breast

Contact Info

Product

Resources

About